GHK-Cu: limits of adverse-event evidence
Maquart and colleagues studied the GHK-Cu copper complex in fibroblast cultures, measuring collagen synthesis. The inspected abstract of this 1988 study gives no clinical adverse-event frequencies. [1]
A cell experiment cannot establish adverse reactions or safety of GHK-Cu administration in humans. It also does not establish risks for a particular reagent batch or a blend with other compounds. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Clinical adverse events | Fibroblast cultures (cell experiment measuring collagen synthesis) | The abstract gives no clinical adverse-event frequencies; a cell experiment cannot establish adverse reactions or safety of administration in humans | [1] |
References
- Maquart FX et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ https://doi.org/10.1016/0014-5793(88)80509-X.